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Abstract The ratio of mutant to wildtype myosin heavy chain
(L-isoform, L-MHC) in the soleus muscle of patients with
familial hypertrophic cardiomyopathy was determined by a
combination of HPLC, mass spectrometry and capillary zone
electrophoresis. In two patients, one with a Val 606 Met
mutation and another with a Gly 584 Arg mutation, the fraction
of mutant L-MHC was only 12 þ 6% and 23 þ 0.7% of total L-
MHC, respectively. These results demonstrate the necessity to
determine the ratio of mutant to wildtype protein for the
interpretation of functional studies on biopsy material from
heterozygous patients with an inherited disease.
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1. Introduction
Several inherited diseases are caused by missense mutations
that lead to malfunction of the mutant protein. Examples of
such diseases are sickle cell anemia, caused by the exchange of
a single amino acid in the hemoglobin L-chain [1], or several
diseases of the skeletal muscles, caused by missense mutations
in genes encoding ion channels [2]. The discovery of mutations
in sarcomeric proteins as the cause of familial hypertrophic
cardiomyopathy (FHC) extended the list of inherited diseases
that are caused by missense mutations. In some families this
disease is caused by missense mutations in the L-isoform of
the myosin heavy chain (L-MHC) [3,4]. FHC, however, is a
very heterogeneous disease. Even members of the same family,
i.e. patients with the same mutation, have di¡erent clinical
symptoms and a very di¡erent prognosis [5]. The reason for
this variability is still unknown. Since the patients are hetero-
zygous, mutant and wildtype L-MHC are coexpressed. It is,
however, not known whether the ratio of mutant to wildtype
protein is 1:1. A variation of the ratio of mutant to wildtype
protein from patient to patient might explain the wide spec-
trum of clinical symptoms even within the same family with
the identical mutation.
To test this hypothesis, we quanti¢ed the ratio of mutant to
wildtype protein. This quanti¢cation is hampered by the large
size of the L-MHC (1935 amino acids) [6,7], because the phys-
ico-chemical properties of such a large protein are not su⁄-
ciently altered by the exchange of a single amino acid for the
mutant and wildtype forms to be separated. This becomes
even more di⁄cult when amino acids are exchanged for other
amino acids of similar properties.
In the present study, we have developed a new method for
the quanti¢cation of the ratio of mutant to wildtype protein,
which can be applied to large proteins and to any type of
amino acid exchange. To use this approach, the amino acid
sequence of the protein and the type of mutation must be
known. In our strategy, we ¢rst digested the large protein
with a speci¢c endoproteinase, so that a mixture of well de-
¢ned peptides was generated. Digestion of the wildtype and
the mutant protein generates identical peptides except for the
one peptide that includes the position of the point mutation.
This peptide exists in two forms, the wildtype peptide and the
mutant peptide. Selecting a suitable endoproteinase yields a
pair of mutant and wildtype peptides with su⁄ciently di¡erent
physico-chemical properties for successful separation.
Because the digestion of a large protein generates a very
complex mixture of numerous peptides, a two-step separation
is used to eventually isolate pure mutant and wildtype pepti-
des. First, the digest is fractionated by HPLC. Second, each
fraction of the HPLC run, still containing a mixture of pep-
tides, is searched for the mutant and the wildtype peptide by
mass spectrometry (MS). This search by MS involves two
steps, ¢rst determination of the molecular weight to identify
candidate peptides, and second amino acid sequencing of the
candidate peptides which are still in the peptide mixtures [8],
which would not be possible with Edman sequencing.
Since MS does not allow quantitation of the amount of
peptides present in the starting material, the fractions of the
¢rst HPLC run that contained wildtype and mutant peptide
respectively were further separated by capillary zone electro-
phoresis (CZE) to achieve baseline separation for quanti¢ca-
tion of the wildtype and the mutant peptide from the peak
areas. Relevant peaks were identi¢ed with synthetic peptides
that served both as markers and as standards.
We applied this method to two di¡erent missense mutations
in the L-MHC causing FHC. In one patient, Val is replaced
by Met at position 606 (Val 606 Met mutation), and a Gly
584 Arg mutation was found in the other patient. In this
study, we took advantage of the fact that the L-MHC is ex-
pressed not only in the ventricle but also in slow skeletal
muscles like the soleus muscle.
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2. Materials and methods
2.1. Preparation of myosin
Fiber bundles (1^3 mm diameter, 5^10 mm length) from the soleus
muscle were obtained from patients with FHC and healthy controls.
These bundles were prepared as previously described [9^11] and stored
in liquid nitrogen [12]. While still frozen, each bundle was homogen-
ized and myosin was extracted with 150 Wl of a modi¢ed Hasselbach-
Schneider solution (0.5 M NaCl, 10 mM HEPES, 5 mM MgCl2, 2.5
mM ATP; potassium in the original Hasselbach-Schneider solution
was replaced by sodium) for 15 min at 4‡C. After centrifugation, the
supernatant was diluted with 10 volumes of water and myosin was
allowed to precipitate at 4‡C for 24 h. The supernatant was discarded
and the precipitate resuspended in 100 Wl 0.1% tri£uoroacetic acid
(TFA) and then lyophilized.
2.2. Digestion of myosin by endoproteinase Lys-C
Lyophilized myosin was digested with 5 Wg endoproteinase Lys-C
(Boehringer Mannheim, Germany) in 0.1 M NH4HCO3 for 24 h at
37‡C. The digest was lyophilized.
2.3. HPLC separation of peptides
The lyophilized peptides were dissolved in 50 Wl 0.1% TFA and
chromatography was carried out using a 2 mmU250 mm C18 re-
versed phase column (Reprosil C18, 5 Wm, 12 nm, Dr. Maisch, Feld-
buch, Germany) at a £ow rate of 0.2 ml/min. The column temperature
was maintained at 30‡C. A linear gradient using 0.1% (v/v) TFA in
water (solvent A) and 0.1% TFA in 40% methanol, 40% 2-propanol
in water (solvent B) was generated, starting with 10% of solvent B
increasing to 70% of solvent B within 60 min. UV absorbance
was monitored at 220 and 280 nm. Fractions were collected every
minute.
2.4. Mass spectrometry
Mass spectrometric analysis was carried out with an API III triple
stage quadrupole mass spectrometer (PE-SCIEX, Langen, Germany),
equipped with articulated ion spray. The HPLC fractions were either
used directly for the mass spectrometric analysis or lyophilized and
then redissolved in 0.5% formic acid, 50% acetonitrile in water (v/v).
Solutions were infused at a £ow rate of 5 Wl/min, using a syringe
pump.
Molecular weight was determined in the positive ion mode in
a mass/charge (m/z) range from 400 to 2400. All settings of the in-
strument were optimized each day during the calibration procedure.
For mass spectrometric sequencing of peptides by MS/MS, we
used argon as collision gas. Mass spectra were evaluated with the
MacSpec (PE-SCIEX, Langen, Germany) and SHERPA [13] pro-
grams.
2.5. Capillary zone electrophoresis
CZE was performed with an uncoated 50 WmU50 cm fused silica
capillary. The separation bu¡er was 100 mM sodium phosphate, pH
3.0, with 0.02% hydroxymethylcellulose. The peptides were separated
at 25‡C with a constant current of 80 WA, UV absorbance was re-
corded at 200 nm. The sample was applied with low pressure at a £ow
rate of about 6 nl/min. A standard peptide (Low pH Mobility Stand-
ard, PE-Applied Biosystems) was added to each sample to control the
sample volume that was applied.
Synthetic peptides were used for the identi¢cation of peaks in the
CZE. These peptides were synthesized with the FMOC strategy, using
a 430 A peptide synthesizer (PE-Applied Biosystems).
2.6. SDS-PAGE
SDS-PAGE was carried out using the PhastSystem (Pharmacia Bio-
tech). 12.5% Phastgels were used and the sample bu¡er was 10 mM
Tris-HCl, 1 mM EDTA, 2.5% SDS, 5.0% 2-mercaptoethanol and
0.01% bromophenol blue. Gels were stained with PhastGel Blue R
(Pharmacia Biotech).
3. Results
The general procedure is illustrated in the £ow chart in
Fig. 1.
3.1. Isolation of myosin from ¢ber bundles
Myosin was isolated from soleus muscle tissue by high salt
extraction and subsequent precipitation. The purity of the
myosin was checked by SDS-PAGE (Fig. 2). No impurity
was detectable by staining the gel with Coomassie brilliant
blue. We found this degree of purity to be su⁄cient for fur-
ther analysis of the mutant and wildtype protein. Whole my-
osin, i.e. heavy chains and light chains, was isolated by this
high salt extraction. Only 50^70% of the total myosin was
isolated by this method. The yield increased with increasing
time of extraction, but contamination with other proteins also
increased. Therefore, we preferred an extraction time of 15
min, despite the incomplete extraction.
3.2. Digestion of myosin and HPLC separation
For digestion we used the endoproteinase Lys-C. This en-
zyme cleaves the peptide bond very speci¢cally at the carbox-
ylic site of lysine. From the sequence of the L-MHC, it is
expected that digestion by endoproteinase Lys-C generates
more than 200 peptides ranging in length from 3 to 37 amino
acids. The peptide including position 606 is 13 amino acids
long. The wildtype peptide has a molecular weight of 1474.5,
and the mutant peptide 1506.5. The di¡erence equals the mass
di¡erence between Val and Met. Unexpectedly large frag-
ments, e.g. resulting from incomplete digestion, were not
found by MS.
The endoproteinase Lys-C digest was ¢rst fractionated by
HPLC. A typical chromatogram is shown in Fig. 3. There is a
large number of overlapping peaks, i.e. the resolution is poor,
due to the large number of peptides generated by the digest.
Since the total number of peaks is much smaller than 200, it is
expected that individual peaks still contain several di¡erent
peptides. The limited resolution makes a quantitative analysis
of individual peptides impossible. Therefore the fractions con-
Fig. 1. Flow chart showing the general approach for the quanti¢ca-
tion of the ratio of mutant to wildtype protein.
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taining wildtype and mutant peptide had ¢rst to be identi¢ed
by MS and then further separated by CZE.
3.3. Mass spectrometry
To identify the HPLC fractions that contain wildtype and
mutant peptide, each HPLC fraction was analyzed by ESI-
MS. Fig. 4a shows a mass spectrum of one HPLC fraction in
which two cations with an m/z of 1476.1 and 738.5 were
detected, corresponding to the m/z ratio of a single and a
double positively charged peptide, respectively, i.e. with m/z
ratios expected for the wildtype peptide. In a second HPLC
fraction (Fig. 4b), a cation with m/z of 1507.5 was found,
corresponding to the m/z expected for a single charged peptide
with the mass of the mutant peptide. In a control experiment
with muscle tissue from a healthy individual, we could only
detect the wildtype peptide, while the second fraction did not
show the peak seen for the mutant peptide.
To con¢rm that the identi¢ed ions represent ions originat-
ing from wildtype and mutant peptides, we determined their
amino acid sequences by mass spectrometry (MS/MS). Se-
quencing of peptides by MS/MS, using a triple quadrupole
mass spectrometer [8], is achieved as follows: the ion of inter-
est (i.e. the charged peptide) is selected by its speci¢c m/z
value in the ¢rst quadrupole chamber, and other ions are
discarded. This selected peptide (called parent ion) is dissoci-
ated into fragments (daughter ions) by collision with argon
atoms in the second chamber. These fragments are separated
and detected in the third quadrupole chamber. In the frag-
mentation process, mainly the peptide bond is cleaved and the
charge remains associated with one of the two fragments.
When the N-terminal fragment is charged, it is called a b-
ion, and when the C-terminal fragment is charged, it is called
a y-ion. De¢ned by the m/z ratio, two series of daughter ions
are generated by the fragmentation of the parent ions, a b-
series and a y-series. The di¡erences in the molecular weight
between nearest neighbor ions of one series correspond to the
molecular weight of one amino acid and so the sequence of
the peptide can be reconstructed from the series of daughter
ions. The sequencing spectra of the wildtype and mutant pep-
tide are shown in Fig. 5. Note the mass (m/z for z = 1) di¡er-
ence between daughter ions y5 and y6 in the sequencing spec-
tra of the wildtype and the mutant peptide. This di¡erence is
caused by the di¡erent molecular weights of Val and Met.
Thus, MS/MS analysis allowed us to identify wildtype and
mutant peptide by their amino acid sequence without isolating
pure peptides from the original HPLC fraction [8].
The soleus muscle contains not only the L-isoform but also
various other isoforms of the myosin heavy chain. The com-
position of these isoforms is variable depending on training,
humoral and disease status. Therefore the identi¢cation of
peptides from the L-isoform by sequencing is necessary to
avoid errors originating from the detection of peptides from
other isoforms. Since the amino acid sequences of the peptides
used for the quanti¢cation of the Val 606 Met and the Gly
584 Arg mutation are unique for the L-isoform as found by
comparison with all known amino acid sequences of human
MHC, other isoforms do not interfere with the quanti¢cation
of the ratio of mutant to wildtype L-MHC.
Fig. 2. SDS-PAGE. Lane 1: molecular weight marker; lane 2: puri-
¢ed myosin after extraction and precipitation; lane 3: remaining
muscle tissue after extraction of myosin. Note that the heavy chain
and the light chains were extracted. The muscle tissue still contained
some myosin after extraction.
Fig. 3. HPLC chromatogram of the mixture of peptides generated by the digestion of myosin by endoproteinase Lys-C. Fraction 1 contains
the wildtype peptide, fraction 2 the mutant peptide.
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3.4. Capillary zone electrophoresis
Since there are no suitable standards, MS with peptides
does not allow quantitation of the amount of peptides in
the starting material [14], i.e. the peak area cannot be directly
used to estimate the amount of peptide in the HPLC fraction
applied to the mass spectrometer. Thus, for quanti¢cation we
used CZE to achieve baseline separation of the peptides con-
tained in the two HPLC fractions that include wildtype or
mutant peptide, such that both peptides could be quanti¢ed
from their corresponding peak areas. Fig. 6 shows the electro-
pherograms. Note that wildtype and mutant peptide have the
same migration time. This means that they could not have
been separated if they had been present within the same
HPLC fraction. Thus, successful separation into two di¡erent
fractions by the initial HPLC run was essential for the sepa-
ration and quanti¢cation of wildtype and mutant peptides. In
control runs, synthetic wildtype and mutant peptides were
used to identify the relevant peaks in the CZE runs, and to
calibrate the peak areas. The ratio of mutant to wildtype
peptide was evaluated from the corresponding peak areas.
Analyzing ¢ve ¢ber bundles from one patient with the Val
606 Met mutation with this protocol, we found only
12 þ 6% of total L-MHC as mutant heavy chain.
3.5. Controls
To exclude systematic errors in the analytical procedure, we
carried out several control experiments. (i) Synthetic peptides
were used to demonstrate that wildtype and mutant peptide
have the same UV absorbance. (ii) It was further demon-
strated that the peak area in the electropherogram is a linear
function of the amount of applied peptide. (iii) Every sample
analyzed by CZE contained a known amount of a synthetic
standard peptide (Low pH Mobility Standard, PE-Applied
Biosystems) to correct £uctuations in the sample application
and increasing concentrations of peptides in the samples due
to evaporation of solvent prior to loading on the CZE. The
migration time of this standard peptide was di¡erent from the
mutant and the wildtype peptide.
(iv) Detectable loss of a mutant or wildtype fragment in the
analytical procedure was excluded by the following control
experiment: the digest of L-MHC from a healthy individual
was divided into two equal parts, and known amounts of
synthetic peptides (wildtype and mutant) were added to one
part. The whole analytical procedure was carried out with
both parts. To estimate the detected amount of synthetic wild-
type and mutant peptides, the corresponding peak areas of the
Fig. 4. a: Mass spectrum of the HPLC fraction containing the wild-
type peptide. The peaks of the single charged peptide (m/z = 1476.1)
and the double charged peptide (m/z = 738.5) are labeled by arrows.
The intensity of the peaks is normalized to the highest peak. b:
Mass spectrum of the HPLC fraction containing the mutant pep-
tide. The peak of the single charged peptide (m/z = 1507.7) is labeled
by an arrow. In contrast to the wildtype peptide, the double
charged mutant peptide could not be detected. The highest peak
( = 100%) is not shown in this spectrum.
Fig. 5. Sequencing spectra of the wildtype peptide (a) and the mu-
tant peptide (b). The mass di¡erence between ions y5 and y6 (la-
beled with arrows) corresponds to valine in a and to methionine in
b, showing the Val 606 Met mutation. This analysis was carried out
with HPLC fractions of the endoproteinase Lys-C digest of myosin,
which were further analyzed by CZE.
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sample without synthetic peptides were subtracted from the
total peak areas of the sample with the synthetic peptides. For
both peptides (wildtype and mutant), the remaining peak area,
i.e. the amount of peptide detected in the CZE run, was es-
sentially identical to the amount initially added to the digest,
meaning there was no loss, speci¢cally no unequal loss, of
wildtype and mutant peptide.
(v) To estimate errors in the quanti¢cation, we carried out
two further controls; ¢rst we ran the HPLC and subsequent
CZE analysis with synthetic peptides under exactly the same
conditions as with the digests. Running ¢ve test samples, we
found a standard error of þ 12% of the observed mean value.
Analyzing one sample of a synthetic peptide four times with
CZE, the standard error was þ 4% of the observed mean
value.
Once the speci¢c procedure had been established (prepara-
tion of synthetic peptides, identi¢cation of the relevant frac-
tions of the HPLC separation step, etc.), quanti¢cation of
mutant to wildtype protein content of a tissue sample required
some 3 days, mainly due to the time required for precipitation
of extracted myosin and its digestion.
3.6. Analysis of the Gly 584 Arg mutation
We applied the same procedure to L-MHC with a Gly 584
Arg mutation. One remarkable di¡erence to the Val 606 Met
mutation was that wildtype and mutant peptide eluted togeth-
er in the same fraction in the HPLC run. These peptides,
however, had di¡erent migration times in the CZE so that
they were separated at this step. This illustrates that separa-
tion of wildtype and mutant peptide by the initial HPLC run
is not essential if they can be separated by CZE. Here, the
HPLC run only serves for an initial fractionation of the large
number of peptides. Analysis of four ¢ber bundles from one
patient with the Gly 584 Arg mutation yielded a fraction of
mutant L-MHC of 23 þ 0.7% of total L-MHC. For the Gly
584 Arg mutation, we also found that there was no loss of
wildtype or mutant peptide. This was tested again using syn-
thetic peptides as described in Section 3.5.
4. Discussion
The aim of our study was to develop a generally applicable
procedure that allows quanti¢cation of the ratio of mutant to
wildtype protein for large molecules, whose physico-chemical
properties are not su⁄ciently changed by a single amino acid
exchange such that the mutant and the wildtype protein can
easily be separated by standard methods. We used L-MHC as
an example of such a large protein and demonstrated the
potential of our approach by analyzing two mutations, Val
606 Met and Gly 584 Arg. The Val 606 Met mutation is a
particularly di⁄cult example since both amino acids have very
similar properties. We succeeded using a combination of en-
zymatic digestion, HPLC, MS and CZE. Previously, Cuda et
al. [15] used an approach based on peptide mapping and
Western blot analysis. However, this method has two disad-
vantages. (i) The protein has to be cleaved right at the point
of the mutation. For some mutations, there is no appropriate
enzymatic or chemical digest. (ii) For each mutation, a speci¢c
anti-peptide antibody has to be raised. Some amino acid se-
quences, however, are only poor antigens, which is presum-
ably the reason for our failure when trying to apply this
method to the Val 606 Met and the Gly 584 Arg mutations.
We therefore attempted to establish an approach which can
generally be applied for the quanti¢cation of the ratio of
mutant to wildtype protein, independent of the type of protein
and of the type of amino acid exchange. The approach pre-
sented here only fails for the exchange of Leu to Ile, because
of their identical molecular weights. With this new method,
we were able to show that in the soleus muscle from two
patients with FHC the fraction of mutant L-MHC is only
12 þ 6% (Val 606 Met mutation) and 23 þ 0.7% (Gly 584
Arg mutation) of total L-MHC. In contrast to the Gly 584
Arg mutation, the analysis of the Val 606 Met mutation has a
Fig. 6. Electropherograms of the HPLC fraction containing the
wildtype peptide (a) and the HPLC fraction containing the mutant
peptide (b). Both HPLC fractions are a mixture of peptides that are
separated by CZE. In both electropherograms shown here, the peak
with the lowest migration time is a standard peptide (Low pH Mo-
bility Standard, PE-Applied Biosystems).
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large standard error ( þ 50%), although both mutations were
analyzed by the same procedure. One explanation for the
di¡erent standard errors may be di¡erences in the starting
material, for instance a large variation in the ratio of mutant
to wildtype protein among di¡erent ¢ber bundles within the
biopsy with the Val 606 Met mutation, whereas the biopsy
material with the Gly 584 Arg mutation may have been more
homogeneous. In addition, the small standard deviation might
result from the fact that both wildtype and mutant fragments
eluted in the same HPLC fraction. The two fragments were
therefore analyzed within one CZE run, i.e., the correspond-
ing peak areas could directly be related without the need of a
standard peptide for calibration.
There are several requirements which must be met for a
reliable determination of the ratio of mutant to wildtype pro-
tein. The HPLC fractions with wildtype and mutant peptide
have to be identi¢ed as well as the corresponding peaks in the
CZE. We found sequencing by mass spectrometry and the use
of synthetic peptides as standards in the CZE to be suitable to
meet these goals. The synthetic peptides were also indispens-
able tools to show that (a) wildtype and mutant peptide had
the same UV absorbance in the CZE, (b) the peak area is
proportional to the amount of peptide and (c) the recovery
of both peptides is identical. The last point is of particular
importance because di¡erent peptides may, for instance,
adsorb to the surfaces of reaction vessels to a di¡erent extent,
so that their recovery in the analytical procedure might di¡er.
Another source of error could be the di¡erential extraction
of the wildtype and mutant myosins in the ¢rst step of the
procedure. This, however, is unlikely, because mutations in
the globular head domain are not expected to have much
e¡ect on attractive forces between the tail domains of myosin
molecules that form the myosin ¢laments. In addition, the
exchange of only one amino acid in such a large protein has
only little e¡ect on physico-chemical properties like solubility.
Due to the complexity of the mixture of peptides resulting
from the digestion of a large protein, two separation techni-
ques are necessary to achieve su⁄cient resolution for quanti-
¢cation of the peptides. As we have shown in our analysis, it
is not important whether the wildtype and the mutant peptide
are separated in the ¢rst or the second step (HPLC or CZE).
We used the combination of RP-HPLC and CZE, but the
combination of other separation techniques may also be pos-
sible, if they have di¡erent physico-chemical principles of sep-
aration. The combination of di¡erent separation methods ex-
tends the range of proteins that can be analyzed with our
method. In addition, the use of enzymatic or chemical digests
other than the endoproteinase Lys-C digest makes the method
even more versatile. While in the approach of Cuda et al. [15],
cleavage has to occur right at the point of mutation, our
method only requires that cleavage generates a peptide that
includes the mutated position and which is small enough that
the mutation changes its physico-chemical properties su⁄-
ciently for separation. Therefore, one can choose from a
wide variety of speci¢c endoproteinases or a speci¢c chemical
cleavage.
In contrast to our results, Malinchik et al. [16] reported the
presence of equal amounts of mutant and wildtype L-MHC in
the soleus muscle of a patient with FHC caused by an Arg 403
Gln mutation. Taken together with the data presented here,
this shows that the ratio of mutant to wildtype L-MHC can
vary greatly, at least for di¡erent mutations. Di¡erences in the
ratio of mutant to wildtype L-MHC may be caused by di¡er-
ences in the transcription of the mutant gene, di¡erences in
the translation or in the lifetime of the mutant mRNA or
di¡erences in the incorporation of the mutant protein into
the contractile apparatus. Since the mutations are discovered
by single-strand conformation polymorphism, a di¡erent con-
formation of the mutant mRNA is possible. Therefore, the
translation may be impaired or the lifetime of the mutant
mRNA may be shorter, so that there is less mutant than wild-
type mRNA. That a decreased translation of mutant mRNA,
however, is also a possible reason for unequal amounts of
wildtype and mutant protein was demonstrated by Choong
et al. [17]. These authors reported that, in COS cells, expres-
sion of the human androgen receptor with a missense muta-
tion is reduced compared to the wildtype androgen receptor,
while the amounts of mutant and wildtype mRNA were equal.
With myosin binding protein C Rottbauer et al. [18] showed
the presence of the mutant mRNA but the virtual absence of
the corresponding protein. But there is also evidence from
transgenic animals that the mutant mRNAs are translated
[19,20], in some cases even in relatively high levels. Some
results suggest that changes in protein stoichiometry may be
relevant for the degree of myo¢bril disorder in sarcomeric
protein mutations [21]. This may also be the case with mis-
sense mutations in the myosin heavy chain causing FHC.
Due to the small fraction of mutant L-MHC found in this
study, while Malinchik et al. [16] found 50% for the Arg 403
Gln mutation, the interpretation of functional studies on bi-
opsy material from patients with FHC requires quanti¢cation
of the mutant protein. Otherwise, di¡erences in functional
impairment may be mistaken for speci¢c e¡ects of the di¡er-
ent mutations, while they may simply result from di¡erences
in the presence of mutant protein.
As starting material we used ¢ber bundles which were
treated with a skinning solution, so that all soluble proteins
were lost. Only the myosin integrated into the sarcomeric
structure was analyzed. This is advantageous, because the
detection of soluble mutant myosin that is not integrated
into the contractile apparatus would interfere with the corre-
lation between the ratio of mutant to wildtype protein and the
functional e¡ects of the mutation; functional studies are being
carried out with skinned ¢bers since this system allows for a
much larger spectrum of functional tests than possible with
native ¢bers.
The reasons for the wide variety of clinical symptoms in
FHC, even within the same family, are still unknown. This
variation may perhaps result from di¡erences in the presence
of mutant L-MHC. With the approach described here, this
hypothesis can now be tested by analyzing biopsies from dif-
ferent members of one family. Another interesting question is
whether the fraction of mutant protein changes with age. This
idea is supported by the observation of Geisterfer-Lowrance
et al. [22], who described a mouse model for FHC. In these
mice, the clinical symptoms of FHC became more severe with
age, and such changes could again be caused by a change in
the ratio of mutant to wildtype protein. The method presented
here for determination of this ratio now allows such questions
to be addressed.
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